Epidemiology of cervical cancer in Colombia;Epidemiología del cáncer de cuello uterino en Colombia

Colombia Medica

Volumn 43, Issue 4, 2012, Pages 298-304

  Muñoz, Nubia ^a,b   Bravo, Luis Eduardo ^c  

^a Instituto Nacional de Cancerología   (Colombia)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c UNIVERSIDAD DEL VALLE   (Colombia)

Author keywords

Cali; Cancer epidemiology; Cervix uteri cancer; Colombia; HPV; HPV vaccines

Indexed keywords

RUBELLA VACCINE; WART VIRUS VACCINE;

CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER SURVIVAL; COLOMBIA; DRUG COST; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; MASS SCREENING; REVIEW; UTERINE CERVIX CANCER; WART VIRUS;

EID: 84871975339     PISSN: 01208322     EISSN: 16579534     Source Type: Journal    
DOI: 10.25100/cm.v43i4.1269     Document Type: Review

References (33)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on 05/06/2012.
2. Almonte M, Sánchez GI, Jerónimo J, Salmerón J, Ferreccio C, Lazcano-Ponce E, et al. Nuevos paradigmas y desafíos en la prevención y control del cáncer de cuello uterino en América Latina. Salud Publica Mex. 2010; Vol. 52(6):544-559.
3. Pardo C, Cendales R. Incidencia estimada y mortalidad por cáncer en Colombia 2002-2006. Bogotá; Instituto Nacional de Cancerología; 2010.
4. Murillo R, Wiesner C, Cendales R, Pineros M, Tovar S. Comprehensive evaluation of cervical cancer screening programs: the case of Colombia. Salud Publica Mex. 2011;53(6):469-77.
5. Piñeros-Petersen M, Pardo-Ramos C, Gamboa-Garay Ó, Hernández-Suárez G. Atlas de mortalidad por cáncer en Colombia. Bogotá: Instituto Nacional de Cancerología-ESE, Instituto Geográfico Agustín Codazzi; 2010.
6. Yepez MC, Bravo LE, Hidalgo A, Jurado DN, Bravo LM, Cancer incidence and mortality in the municipality of Pasto, 1998-2007. Colomb Med. 2012; 43 (4): 256-66
7. Lopez G, Arias N, Arboleda W. Cancer incidence and mortality in Manizales, 2003-2007. Colomb Med. 2012; 43 (4): 281-89
8. Muñoz N. From causality to prevention. The example of cervical cancer: my personal contribution to this fascinating history. Public Health Genomics 2009; 12: 368-71.
9. Muñoz N, Bosch X, Kaldor JM. Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. Br J Cancer 1988; 57 (1): 1-5.
10. Muñoz N, Bosch FX, de Sanjosé S, Tafur L, Izarzugaza I. The causal link between human papillomavirus and invasive cervical cancer: a population based case control study in Colombia and Spain. Int J Cancer. 1992; 52: 743-49.
11. Bosch FX, Muñoz N, de Sanjosé S, Navarro C, Moreo P, Ascunce N, et al. Human papillomavirus and cervical intraepithelial neoplasia grade III/carcinoma in situ: a case-control study in Spain and Colombia. Cancer Epidemiol Biomarkers Prev. 1993; 2: 415-22.
12. Muñoz N, Bosch FX, de Sanjosé S, Herrero R. For the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348 (6): 518-27.
13. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens. Part B: biological agents. Lancet Oncol. 2009; 10 (4): 321-2.
14. Muñoz N, Castellsagué X, de González AB, Gismann L. HPV in the etiology of human cancer. Vaccine 2006; 24 (3): 1-10.
15. Muñoz N, Castellsagué X, Bosch FX, Tafur L, de Sanjosé S, Aristizábal N et al. Difficulty in elucidating the male role in Colombia, a high-risk area for cervical cancer. J Natl Cancer Inst. 1996; 88: 1068-75.
16. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-9.
17. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjosé S, Hammouda D et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-85.
18. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer. Lancet Oncol. 2010; 11: 1048-56.
19. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. Natl Cancer Inst. 2010; 102 (5): 325-39.
20. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13(1):89-99.
21. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HP infection and anal intraepithelial neoplasia. N Engl J Med. 2011; 365 (17): 1576-85.
22. Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodríguez AC. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 2011; 12 (9): 862.
23. World Health Organization. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009; 84: 118-31.
24. GAVI Alliance. Human papillomavirus vaccine. New and underused vaccines support. Types of support. Geneva, Switzerland. GAVI Alliance; 2012.
25. Kreimer AR, Rodríguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011; 103 (19): 1444-51.
26. Murillo R, Almonte M, Pereira A. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 2008; 26 Suppl 11:L37-48).
27. Cuzick, J., M. Arbyn, R. Sankaranarayanan, V. Tsu, G. Ronco, M. H. Mayrand, J. Dillner and C. J. Meijer (2008) Overview of human papillomavirus-based and other novel options for cervical. Vaccine, 26 (Suppl) 10, K29-41.
28. Sankaranarayanan R, Nene BM, Shastri SS. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385-94.
29. Gamboa O.,Chicaíza L, García-Molina M, Díaz J, González M, Murillo. Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. Salud Publica Mex 2008;50:276-285.
30. Murillo R, Luna J, Gamboa O, Osorio E, Bonilla J, Cendales R. Cervical cancer screening with naked-eye visual inspection in Colombia. Int J Gynaecol Obstet. 2010;109:230-4.
31. Muñoz N and Herrero Prevention of cervical cancer in women;s hands: Mexico leads the way. Lancet 2011: 378
32. Qiao YL, Sellors J, Eder PS et al. Anew test for cervical cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural Chin Lancet Oncology 2008; 9:929-36
33. Muñoz, N., Franco, E.L., Herrero, R., Andrus, J.K., de Quadros, C.A., Bosch, F.X. Recommendations for Cervical Cancer Prevention in Latin America and the Caribbean. Vaccine 2008;26(11), L96-L107